At the news
? NEUTRALIMPACT 4/10 CLUSTER filed Mar 16, 2026 at 16:31 ET
United Therapeutics CEO Martine Rothblatt and other insiders engaged in a series of derivative exercises and open-market sales over the past week, generating $2.8 million in total proceeds from stock sales. The activity is primarily tied to option exercises and tax-related sales, with the CEO accounting for the majority of transactions.
- CEO Martine Rothblatt exercised options for 95,000 shares across multiple days (10 tranches of 9,500 shares), with 5 tranches at $146.03 (total value $6.94M) and 5 at $0 (non-cash).
- Rothblatt sold 852 shares in open-market transactions totaling $447,085.17 at prices between $520.34 and $531.21.
- EVP Paul Mahon exercised options for 16,600 shares at $146.03 (value $2.42M) and sold 753 shares for $397,183.86.
- Director Jan Malcolm sold 45 shares for $24,007.95.
Before · The news · First close · A day later · A week later
Replay the market's reaction
Step through every 5 minutes around the news, then see how it compares with similar events.
Subscribe for Full Access